Global Radioimmunotherapy Supply, Demand and Key Producers, 2023-2029
The global Radioimmunotherapy market size is expected to reach $ 3159.2 million by 2029, rising at a market growth of 16.7% CAGR during the forecast period (2023-2029).
Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non Hodgkin Lymphoma.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report studies the global Radioimmunotherapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radioimmunotherapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radioimmunotherapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radioimmunotherapy total market, 2018-2029, (USD Million)
Global Radioimmunotherapy total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Radioimmunotherapy total market, key domestic companies and share, (USD Million)
Global Radioimmunotherapy revenue by player and market share 2018-2023, (USD Million)
Global Radioimmunotherapy total market by Type, CAGR, 2018-2029, (USD Million)
Global Radioimmunotherapy total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Radioimmunotherapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Radioimmunotherapy market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Radioimmunotherapy Market, By Region:
1. How big is the global Radioimmunotherapy market?
2. What is the demand of the global Radioimmunotherapy market?
3. What is the year over year growth of the global Radioimmunotherapy market?
4. What is the total value of the global Radioimmunotherapy market?
5. Who are the major players in the global Radioimmunotherapy market?
6. What are the growth factors driving the market demand?
Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non Hodgkin Lymphoma.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report studies the global Radioimmunotherapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Radioimmunotherapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radioimmunotherapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Radioimmunotherapy total market, 2018-2029, (USD Million)
Global Radioimmunotherapy total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Radioimmunotherapy total market, key domestic companies and share, (USD Million)
Global Radioimmunotherapy revenue by player and market share 2018-2023, (USD Million)
Global Radioimmunotherapy total market by Type, CAGR, 2018-2029, (USD Million)
Global Radioimmunotherapy total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Radioimmunotherapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Radioimmunotherapy market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Radioimmunotherapy Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Gilead Sciences
- Clarity Pharmaceuticals
- Curasight
- Nordic Nanovector
- Philogen
- RadioMedix
- Telix Pharmaceuticals
- Orano Med
- Actinium Pharmaceuticals
- Y-mAbs Therapeutics
- Fusion Pharmaceuticals
1. How big is the global Radioimmunotherapy market?
2. What is the demand of the global Radioimmunotherapy market?
3. What is the year over year growth of the global Radioimmunotherapy market?
4. What is the total value of the global Radioimmunotherapy market?
5. Who are the major players in the global Radioimmunotherapy market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Radioimmunotherapy Introduction
1.2 World Radioimmunotherapy Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Radioimmunotherapy Total Market by Region (by Headquarter Location)
1.3.1 World Radioimmunotherapy Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Radioimmunotherapy Market Size (2018-2029)
1.3.3 China Radioimmunotherapy Market Size (2018-2029)
1.3.4 Europe Radioimmunotherapy Market Size (2018-2029)
1.3.5 Japan Radioimmunotherapy Market Size (2018-2029)
1.3.6 South Korea Radioimmunotherapy Market Size (2018-2029)
1.3.7 ASEAN Radioimmunotherapy Market Size (2018-2029)
1.3.8 India Radioimmunotherapy Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radioimmunotherapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Radioimmunotherapy Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Radioimmunotherapy Consumption Value (2018-2029)
2.2 World Radioimmunotherapy Consumption Value by Region
2.2.1 World Radioimmunotherapy Consumption Value by Region (2018-2023)
2.2.2 World Radioimmunotherapy Consumption Value Forecast by Region (2024-2029)
2.3 United States Radioimmunotherapy Consumption Value (2018-2029)
2.4 China Radioimmunotherapy Consumption Value (2018-2029)
2.5 Europe Radioimmunotherapy Consumption Value (2018-2029)
2.6 Japan Radioimmunotherapy Consumption Value (2018-2029)
2.7 South Korea Radioimmunotherapy Consumption Value (2018-2029)
2.8 ASEAN Radioimmunotherapy Consumption Value (2018-2029)
2.9 India Radioimmunotherapy Consumption Value (2018-2029)
3 WORLD RADIOIMMUNOTHERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Radioimmunotherapy Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radioimmunotherapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radioimmunotherapy in 2022
3.2.3 Global Concentration Ratios (CR8) for Radioimmunotherapy in 2022
3.3 Radioimmunotherapy Company Evaluation Quadrant
3.4 Radioimmunotherapy Market: Overall Company Footprint Analysis
3.4.1 Radioimmunotherapy Market: Region Footprint
3.4.2 Radioimmunotherapy Market: Company Product Type Footprint
3.4.3 Radioimmunotherapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radioimmunotherapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radioimmunotherapy Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Radioimmunotherapy Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Radioimmunotherapy Consumption Value Comparison
4.2.1 United States VS China: Radioimmunotherapy Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Radioimmunotherapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Radioimmunotherapy Companies and Market Share, 2018-2023
4.3.1 United States Based Radioimmunotherapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radioimmunotherapy Revenue, (2018-2023)
4.4 China Based Companies Radioimmunotherapy Revenue and Market Share, 2018-2023
4.4.1 China Based Radioimmunotherapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radioimmunotherapy Revenue, (2018-2023)
4.5 Rest of World Based Radioimmunotherapy Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Radioimmunotherapy Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Radioimmunotherapy Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Radioimmunotherapy Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Beta-emitting
5.2.2 Targeted Alpha Therapy
5.3 Market Segment by Type
5.3.1 World Radioimmunotherapy Market Size by Type (2018-2023)
5.3.2 World Radioimmunotherapy Market Size by Type (2024-2029)
5.3.3 World Radioimmunotherapy Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Radioimmunotherapy Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Solid Tumor
6.2.2 Non Hodgkin Lymphoma
6.3 Market Segment by Application
6.3.1 World Radioimmunotherapy Market Size by Application (2018-2023)
6.3.2 World Radioimmunotherapy Market Size by Application (2024-2029)
6.3.3 World Radioimmunotherapy Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Radioimmunotherapy Product and Services
7.1.4 Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Radioimmunotherapy Product and Services
7.2.4 Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Lantheus
7.3.1 Lantheus Details
7.3.2 Lantheus Major Business
7.3.3 Lantheus Radioimmunotherapy Product and Services
7.3.4 Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Lantheus Recent Developments/Updates
7.3.6 Lantheus Competitive Strengths & Weaknesses
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Details
7.4.2 Aurobindo Pharma Major Business
7.4.3 Aurobindo Pharma Radioimmunotherapy Product and Services
7.4.4 Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Aurobindo Pharma Recent Developments/Updates
7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.5 Mundipharma
7.5.1 Mundipharma Details
7.5.2 Mundipharma Major Business
7.5.3 Mundipharma Radioimmunotherapy Product and Services
7.5.4 Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Mundipharma Recent Developments/Updates
7.5.6 Mundipharma Competitive Strengths & Weaknesses
7.6 China Isotope & Radiation
7.6.1 China Isotope & Radiation Details
7.6.2 China Isotope & Radiation Major Business
7.6.3 China Isotope & Radiation Radioimmunotherapy Product and Services
7.6.4 China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 China Isotope & Radiation Recent Developments/Updates
7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
7.7 Curium Pharmaceuticals
7.7.1 Curium Pharmaceuticals Details
7.7.2 Curium Pharmaceuticals Major Business
7.7.3 Curium Pharmaceuticals Radioimmunotherapy Product and Services
7.7.4 Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharmaceuticals Recent Developments/Updates
7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Radioimmunotherapy Product and Services
7.8.4 Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 Clarity Pharmaceuticals
7.9.1 Clarity Pharmaceuticals Details
7.9.2 Clarity Pharmaceuticals Major Business
7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Product and Services
7.9.4 Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
7.10 Curasight
7.10.1 Curasight Details
7.10.2 Curasight Major Business
7.10.3 Curasight Radioimmunotherapy Product and Services
7.10.4 Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Curasight Recent Developments/Updates
7.10.6 Curasight Competitive Strengths & Weaknesses
7.11 Nordic Nanovector
7.11.1 Nordic Nanovector Details
7.11.2 Nordic Nanovector Major Business
7.11.3 Nordic Nanovector Radioimmunotherapy Product and Services
7.11.4 Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Nordic Nanovector Recent Developments/Updates
7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses
7.12 Philogen
7.12.1 Philogen Details
7.12.2 Philogen Major Business
7.12.3 Philogen Radioimmunotherapy Product and Services
7.12.4 Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Philogen Recent Developments/Updates
7.12.6 Philogen Competitive Strengths & Weaknesses
7.13 RadioMedix
7.13.1 RadioMedix Details
7.13.2 RadioMedix Major Business
7.13.3 RadioMedix Radioimmunotherapy Product and Services
7.13.4 RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 RadioMedix Recent Developments/Updates
7.13.6 RadioMedix Competitive Strengths & Weaknesses
7.14 Telix Pharmaceuticals
7.14.1 Telix Pharmaceuticals Details
7.14.2 Telix Pharmaceuticals Major Business
7.14.3 Telix Pharmaceuticals Radioimmunotherapy Product and Services
7.14.4 Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Telix Pharmaceuticals Recent Developments/Updates
7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
7.15 Orano Med
7.15.1 Orano Med Details
7.15.2 Orano Med Major Business
7.15.3 Orano Med Radioimmunotherapy Product and Services
7.15.4 Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Orano Med Recent Developments/Updates
7.15.6 Orano Med Competitive Strengths & Weaknesses
7.16 Actinium Pharmaceuticals
7.16.1 Actinium Pharmaceuticals Details
7.16.2 Actinium Pharmaceuticals Major Business
7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Product and Services
7.16.4 Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
7.17 Y-mAbs Therapeutics
7.17.1 Y-mAbs Therapeutics Details
7.17.2 Y-mAbs Therapeutics Major Business
7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Product and Services
7.17.4 Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.18 Fusion Pharmaceuticals
7.18.1 Fusion Pharmaceuticals Details
7.18.2 Fusion Pharmaceuticals Major Business
7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Product and Services
7.18.4 Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Radioimmunotherapy Industry Chain
8.2 Radioimmunotherapy Upstream Analysis
8.3 Radioimmunotherapy Midstream Analysis
8.4 Radioimmunotherapy Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Radioimmunotherapy Introduction
1.2 World Radioimmunotherapy Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Radioimmunotherapy Total Market by Region (by Headquarter Location)
1.3.1 World Radioimmunotherapy Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Radioimmunotherapy Market Size (2018-2029)
1.3.3 China Radioimmunotherapy Market Size (2018-2029)
1.3.4 Europe Radioimmunotherapy Market Size (2018-2029)
1.3.5 Japan Radioimmunotherapy Market Size (2018-2029)
1.3.6 South Korea Radioimmunotherapy Market Size (2018-2029)
1.3.7 ASEAN Radioimmunotherapy Market Size (2018-2029)
1.3.8 India Radioimmunotherapy Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Radioimmunotherapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Radioimmunotherapy Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Radioimmunotherapy Consumption Value (2018-2029)
2.2 World Radioimmunotherapy Consumption Value by Region
2.2.1 World Radioimmunotherapy Consumption Value by Region (2018-2023)
2.2.2 World Radioimmunotherapy Consumption Value Forecast by Region (2024-2029)
2.3 United States Radioimmunotherapy Consumption Value (2018-2029)
2.4 China Radioimmunotherapy Consumption Value (2018-2029)
2.5 Europe Radioimmunotherapy Consumption Value (2018-2029)
2.6 Japan Radioimmunotherapy Consumption Value (2018-2029)
2.7 South Korea Radioimmunotherapy Consumption Value (2018-2029)
2.8 ASEAN Radioimmunotherapy Consumption Value (2018-2029)
2.9 India Radioimmunotherapy Consumption Value (2018-2029)
3 WORLD RADIOIMMUNOTHERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Radioimmunotherapy Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Radioimmunotherapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Radioimmunotherapy in 2022
3.2.3 Global Concentration Ratios (CR8) for Radioimmunotherapy in 2022
3.3 Radioimmunotherapy Company Evaluation Quadrant
3.4 Radioimmunotherapy Market: Overall Company Footprint Analysis
3.4.1 Radioimmunotherapy Market: Region Footprint
3.4.2 Radioimmunotherapy Market: Company Product Type Footprint
3.4.3 Radioimmunotherapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Radioimmunotherapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Radioimmunotherapy Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Radioimmunotherapy Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Radioimmunotherapy Consumption Value Comparison
4.2.1 United States VS China: Radioimmunotherapy Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Radioimmunotherapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Radioimmunotherapy Companies and Market Share, 2018-2023
4.3.1 United States Based Radioimmunotherapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Radioimmunotherapy Revenue, (2018-2023)
4.4 China Based Companies Radioimmunotherapy Revenue and Market Share, 2018-2023
4.4.1 China Based Radioimmunotherapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Radioimmunotherapy Revenue, (2018-2023)
4.5 Rest of World Based Radioimmunotherapy Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Radioimmunotherapy Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Radioimmunotherapy Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Radioimmunotherapy Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Beta-emitting
5.2.2 Targeted Alpha Therapy
5.3 Market Segment by Type
5.3.1 World Radioimmunotherapy Market Size by Type (2018-2023)
5.3.2 World Radioimmunotherapy Market Size by Type (2024-2029)
5.3.3 World Radioimmunotherapy Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Radioimmunotherapy Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Solid Tumor
6.2.2 Non Hodgkin Lymphoma
6.3 Market Segment by Application
6.3.1 World Radioimmunotherapy Market Size by Application (2018-2023)
6.3.2 World Radioimmunotherapy Market Size by Application (2024-2029)
6.3.3 World Radioimmunotherapy Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Radioimmunotherapy Product and Services
7.1.4 Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Radioimmunotherapy Product and Services
7.2.4 Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Lantheus
7.3.1 Lantheus Details
7.3.2 Lantheus Major Business
7.3.3 Lantheus Radioimmunotherapy Product and Services
7.3.4 Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Lantheus Recent Developments/Updates
7.3.6 Lantheus Competitive Strengths & Weaknesses
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Details
7.4.2 Aurobindo Pharma Major Business
7.4.3 Aurobindo Pharma Radioimmunotherapy Product and Services
7.4.4 Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Aurobindo Pharma Recent Developments/Updates
7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.5 Mundipharma
7.5.1 Mundipharma Details
7.5.2 Mundipharma Major Business
7.5.3 Mundipharma Radioimmunotherapy Product and Services
7.5.4 Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Mundipharma Recent Developments/Updates
7.5.6 Mundipharma Competitive Strengths & Weaknesses
7.6 China Isotope & Radiation
7.6.1 China Isotope & Radiation Details
7.6.2 China Isotope & Radiation Major Business
7.6.3 China Isotope & Radiation Radioimmunotherapy Product and Services
7.6.4 China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 China Isotope & Radiation Recent Developments/Updates
7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
7.7 Curium Pharmaceuticals
7.7.1 Curium Pharmaceuticals Details
7.7.2 Curium Pharmaceuticals Major Business
7.7.3 Curium Pharmaceuticals Radioimmunotherapy Product and Services
7.7.4 Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharmaceuticals Recent Developments/Updates
7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Radioimmunotherapy Product and Services
7.8.4 Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 Clarity Pharmaceuticals
7.9.1 Clarity Pharmaceuticals Details
7.9.2 Clarity Pharmaceuticals Major Business
7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Product and Services
7.9.4 Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
7.10 Curasight
7.10.1 Curasight Details
7.10.2 Curasight Major Business
7.10.3 Curasight Radioimmunotherapy Product and Services
7.10.4 Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Curasight Recent Developments/Updates
7.10.6 Curasight Competitive Strengths & Weaknesses
7.11 Nordic Nanovector
7.11.1 Nordic Nanovector Details
7.11.2 Nordic Nanovector Major Business
7.11.3 Nordic Nanovector Radioimmunotherapy Product and Services
7.11.4 Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Nordic Nanovector Recent Developments/Updates
7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses
7.12 Philogen
7.12.1 Philogen Details
7.12.2 Philogen Major Business
7.12.3 Philogen Radioimmunotherapy Product and Services
7.12.4 Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Philogen Recent Developments/Updates
7.12.6 Philogen Competitive Strengths & Weaknesses
7.13 RadioMedix
7.13.1 RadioMedix Details
7.13.2 RadioMedix Major Business
7.13.3 RadioMedix Radioimmunotherapy Product and Services
7.13.4 RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 RadioMedix Recent Developments/Updates
7.13.6 RadioMedix Competitive Strengths & Weaknesses
7.14 Telix Pharmaceuticals
7.14.1 Telix Pharmaceuticals Details
7.14.2 Telix Pharmaceuticals Major Business
7.14.3 Telix Pharmaceuticals Radioimmunotherapy Product and Services
7.14.4 Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Telix Pharmaceuticals Recent Developments/Updates
7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
7.15 Orano Med
7.15.1 Orano Med Details
7.15.2 Orano Med Major Business
7.15.3 Orano Med Radioimmunotherapy Product and Services
7.15.4 Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Orano Med Recent Developments/Updates
7.15.6 Orano Med Competitive Strengths & Weaknesses
7.16 Actinium Pharmaceuticals
7.16.1 Actinium Pharmaceuticals Details
7.16.2 Actinium Pharmaceuticals Major Business
7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Product and Services
7.16.4 Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
7.17 Y-mAbs Therapeutics
7.17.1 Y-mAbs Therapeutics Details
7.17.2 Y-mAbs Therapeutics Major Business
7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Product and Services
7.17.4 Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.18 Fusion Pharmaceuticals
7.18.1 Fusion Pharmaceuticals Details
7.18.2 Fusion Pharmaceuticals Major Business
7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Product and Services
7.18.4 Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Radioimmunotherapy Industry Chain
8.2 Radioimmunotherapy Upstream Analysis
8.3 Radioimmunotherapy Midstream Analysis
8.4 Radioimmunotherapy Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Radioimmunotherapy Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Radioimmunotherapy Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Radioimmunotherapy Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Radioimmunotherapy Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Radioimmunotherapy Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radioimmunotherapy Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Radioimmunotherapy Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Radioimmunotherapy Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Radioimmunotherapy Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Radioimmunotherapy Players in 2022
Table 12. World Radioimmunotherapy Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Radioimmunotherapy Company Evaluation Quadrant
Table 14. Head Office of Key Radioimmunotherapy Player
Table 15. Radioimmunotherapy Market: Company Product Type Footprint
Table 16. Radioimmunotherapy Market: Company Product Application Footprint
Table 17. Radioimmunotherapy Mergers & Acquisitions Activity
Table 18. United States VS China Radioimmunotherapy Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Radioimmunotherapy Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Radioimmunotherapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radioimmunotherapy Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Radioimmunotherapy Revenue Market Share (2018-2023)
Table 23. China Based Radioimmunotherapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radioimmunotherapy Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Radioimmunotherapy Revenue Market Share (2018-2023)
Table 26. Rest of World Based Radioimmunotherapy Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Radioimmunotherapy Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Radioimmunotherapy Revenue Market Share (2018-2023)
Table 29. World Radioimmunotherapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Radioimmunotherapy Market Size by Type (2018-2023) & (USD Million)
Table 31. World Radioimmunotherapy Market Size by Type (2024-2029) & (USD Million)
Table 32. World Radioimmunotherapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Radioimmunotherapy Market Size by Application (2018-2023) & (USD Million)
Table 34. World Radioimmunotherapy Market Size by Application (2024-2029) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Radioimmunotherapy Product and Services
Table 38. Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Radioimmunotherapy Product and Services
Table 44. Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Lantheus Basic Information, Area Served and Competitors
Table 48. Lantheus Major Business
Table 49. Lantheus Radioimmunotherapy Product and Services
Table 50. Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Lantheus Recent Developments/Updates
Table 52. Lantheus Competitive Strengths & Weaknesses
Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 54. Aurobindo Pharma Major Business
Table 55. Aurobindo Pharma Radioimmunotherapy Product and Services
Table 56. Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Aurobindo Pharma Recent Developments/Updates
Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 59. Mundipharma Basic Information, Area Served and Competitors
Table 60. Mundipharma Major Business
Table 61. Mundipharma Radioimmunotherapy Product and Services
Table 62. Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Mundipharma Recent Developments/Updates
Table 64. Mundipharma Competitive Strengths & Weaknesses
Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors
Table 66. China Isotope & Radiation Major Business
Table 67. China Isotope & Radiation Radioimmunotherapy Product and Services
Table 68. China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. China Isotope & Radiation Recent Developments/Updates
Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Curium Pharmaceuticals Major Business
Table 73. Curium Pharmaceuticals Radioimmunotherapy Product and Services
Table 74. Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharmaceuticals Recent Developments/Updates
Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Radioimmunotherapy Product and Services
Table 80. Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
Table 84. Clarity Pharmaceuticals Major Business
Table 85. Clarity Pharmaceuticals Radioimmunotherapy Product and Services
Table 86. Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Clarity Pharmaceuticals Recent Developments/Updates
Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
Table 89. Curasight Basic Information, Area Served and Competitors
Table 90. Curasight Major Business
Table 91. Curasight Radioimmunotherapy Product and Services
Table 92. Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Curasight Recent Developments/Updates
Table 94. Curasight Competitive Strengths & Weaknesses
Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
Table 96. Nordic Nanovector Major Business
Table 97. Nordic Nanovector Radioimmunotherapy Product and Services
Table 98. Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Nordic Nanovector Recent Developments/Updates
Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
Table 101. Philogen Basic Information, Area Served and Competitors
Table 102. Philogen Major Business
Table 103. Philogen Radioimmunotherapy Product and Services
Table 104. Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Philogen Recent Developments/Updates
Table 106. Philogen Competitive Strengths & Weaknesses
Table 107. RadioMedix Basic Information, Area Served and Competitors
Table 108. RadioMedix Major Business
Table 109. RadioMedix Radioimmunotherapy Product and Services
Table 110. RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. RadioMedix Recent Developments/Updates
Table 112. RadioMedix Competitive Strengths & Weaknesses
Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
Table 114. Telix Pharmaceuticals Major Business
Table 115. Telix Pharmaceuticals Radioimmunotherapy Product and Services
Table 116. Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Telix Pharmaceuticals Recent Developments/Updates
Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 119. Orano Med Basic Information, Area Served and Competitors
Table 120. Orano Med Major Business
Table 121. Orano Med Radioimmunotherapy Product and Services
Table 122. Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Orano Med Recent Developments/Updates
Table 124. Orano Med Competitive Strengths & Weaknesses
Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
Table 126. Actinium Pharmaceuticals Major Business
Table 127. Actinium Pharmaceuticals Radioimmunotherapy Product and Services
Table 128. Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Actinium Pharmaceuticals Recent Developments/Updates
Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 132. Y-mAbs Therapeutics Major Business
Table 133. Y-mAbs Therapeutics Radioimmunotherapy Product and Services
Table 134. Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Y-mAbs Therapeutics Recent Developments/Updates
Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
Table 137. Fusion Pharmaceuticals Major Business
Table 138. Fusion Pharmaceuticals Radioimmunotherapy Product and Services
Table 139. Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Radioimmunotherapy Upstream (Raw Materials)
Table 141. Radioimmunotherapy Typical Customers
List of Figure
Figure 1. Radioimmunotherapy Picture
Figure 2. World Radioimmunotherapy Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Radioimmunotherapy Total Market Size (2018-2029) & (USD Million)
Figure 4. World Radioimmunotherapy Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Radioimmunotherapy Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 13. Radioimmunotherapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 16. World Radioimmunotherapy Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 18. China Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 23. India Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Radioimmunotherapy by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radioimmunotherapy Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radioimmunotherapy Markets in 2022
Figure 27. United States VS China: Radioimmunotherapy Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Radioimmunotherapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Radioimmunotherapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Radioimmunotherapy Market Size Market Share by Type in 2022
Figure 31. Beta-emitting
Figure 32. Targeted Alpha Therapy
Figure 33. World Radioimmunotherapy Market Size Market Share by Type (2018-2029)
Figure 34. World Radioimmunotherapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Radioimmunotherapy Market Size Market Share by Application in 2022
Figure 36. Solid Tumor
Figure 37. Non Hodgkin Lymphoma
Figure 38. Radioimmunotherapy Industrial Chain
Figure 39. Methodology
Figure 40. Research Process and Data Source
Table 1. World Radioimmunotherapy Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Radioimmunotherapy Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Radioimmunotherapy Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Radioimmunotherapy Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Radioimmunotherapy Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Radioimmunotherapy Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Radioimmunotherapy Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Radioimmunotherapy Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Radioimmunotherapy Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Radioimmunotherapy Players in 2022
Table 12. World Radioimmunotherapy Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Radioimmunotherapy Company Evaluation Quadrant
Table 14. Head Office of Key Radioimmunotherapy Player
Table 15. Radioimmunotherapy Market: Company Product Type Footprint
Table 16. Radioimmunotherapy Market: Company Product Application Footprint
Table 17. Radioimmunotherapy Mergers & Acquisitions Activity
Table 18. United States VS China Radioimmunotherapy Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Radioimmunotherapy Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Radioimmunotherapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Radioimmunotherapy Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Radioimmunotherapy Revenue Market Share (2018-2023)
Table 23. China Based Radioimmunotherapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Radioimmunotherapy Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Radioimmunotherapy Revenue Market Share (2018-2023)
Table 26. Rest of World Based Radioimmunotherapy Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Radioimmunotherapy Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Radioimmunotherapy Revenue Market Share (2018-2023)
Table 29. World Radioimmunotherapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Radioimmunotherapy Market Size by Type (2018-2023) & (USD Million)
Table 31. World Radioimmunotherapy Market Size by Type (2024-2029) & (USD Million)
Table 32. World Radioimmunotherapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Radioimmunotherapy Market Size by Application (2018-2023) & (USD Million)
Table 34. World Radioimmunotherapy Market Size by Application (2024-2029) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Radioimmunotherapy Product and Services
Table 38. Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Radioimmunotherapy Product and Services
Table 44. Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Lantheus Basic Information, Area Served and Competitors
Table 48. Lantheus Major Business
Table 49. Lantheus Radioimmunotherapy Product and Services
Table 50. Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Lantheus Recent Developments/Updates
Table 52. Lantheus Competitive Strengths & Weaknesses
Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 54. Aurobindo Pharma Major Business
Table 55. Aurobindo Pharma Radioimmunotherapy Product and Services
Table 56. Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Aurobindo Pharma Recent Developments/Updates
Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 59. Mundipharma Basic Information, Area Served and Competitors
Table 60. Mundipharma Major Business
Table 61. Mundipharma Radioimmunotherapy Product and Services
Table 62. Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Mundipharma Recent Developments/Updates
Table 64. Mundipharma Competitive Strengths & Weaknesses
Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors
Table 66. China Isotope & Radiation Major Business
Table 67. China Isotope & Radiation Radioimmunotherapy Product and Services
Table 68. China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. China Isotope & Radiation Recent Developments/Updates
Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Curium Pharmaceuticals Major Business
Table 73. Curium Pharmaceuticals Radioimmunotherapy Product and Services
Table 74. Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharmaceuticals Recent Developments/Updates
Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Radioimmunotherapy Product and Services
Table 80. Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
Table 84. Clarity Pharmaceuticals Major Business
Table 85. Clarity Pharmaceuticals Radioimmunotherapy Product and Services
Table 86. Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Clarity Pharmaceuticals Recent Developments/Updates
Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
Table 89. Curasight Basic Information, Area Served and Competitors
Table 90. Curasight Major Business
Table 91. Curasight Radioimmunotherapy Product and Services
Table 92. Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Curasight Recent Developments/Updates
Table 94. Curasight Competitive Strengths & Weaknesses
Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
Table 96. Nordic Nanovector Major Business
Table 97. Nordic Nanovector Radioimmunotherapy Product and Services
Table 98. Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Nordic Nanovector Recent Developments/Updates
Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
Table 101. Philogen Basic Information, Area Served and Competitors
Table 102. Philogen Major Business
Table 103. Philogen Radioimmunotherapy Product and Services
Table 104. Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Philogen Recent Developments/Updates
Table 106. Philogen Competitive Strengths & Weaknesses
Table 107. RadioMedix Basic Information, Area Served and Competitors
Table 108. RadioMedix Major Business
Table 109. RadioMedix Radioimmunotherapy Product and Services
Table 110. RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. RadioMedix Recent Developments/Updates
Table 112. RadioMedix Competitive Strengths & Weaknesses
Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
Table 114. Telix Pharmaceuticals Major Business
Table 115. Telix Pharmaceuticals Radioimmunotherapy Product and Services
Table 116. Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Telix Pharmaceuticals Recent Developments/Updates
Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 119. Orano Med Basic Information, Area Served and Competitors
Table 120. Orano Med Major Business
Table 121. Orano Med Radioimmunotherapy Product and Services
Table 122. Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Orano Med Recent Developments/Updates
Table 124. Orano Med Competitive Strengths & Weaknesses
Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
Table 126. Actinium Pharmaceuticals Major Business
Table 127. Actinium Pharmaceuticals Radioimmunotherapy Product and Services
Table 128. Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Actinium Pharmaceuticals Recent Developments/Updates
Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 132. Y-mAbs Therapeutics Major Business
Table 133. Y-mAbs Therapeutics Radioimmunotherapy Product and Services
Table 134. Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Y-mAbs Therapeutics Recent Developments/Updates
Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
Table 137. Fusion Pharmaceuticals Major Business
Table 138. Fusion Pharmaceuticals Radioimmunotherapy Product and Services
Table 139. Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Radioimmunotherapy Upstream (Raw Materials)
Table 141. Radioimmunotherapy Typical Customers
List of Figure
Figure 1. Radioimmunotherapy Picture
Figure 2. World Radioimmunotherapy Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Radioimmunotherapy Total Market Size (2018-2029) & (USD Million)
Figure 4. World Radioimmunotherapy Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Radioimmunotherapy Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Radioimmunotherapy Revenue (2018-2029) & (USD Million)
Figure 13. Radioimmunotherapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 16. World Radioimmunotherapy Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 18. China Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 23. India Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Radioimmunotherapy by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Radioimmunotherapy Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Radioimmunotherapy Markets in 2022
Figure 27. United States VS China: Radioimmunotherapy Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Radioimmunotherapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Radioimmunotherapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Radioimmunotherapy Market Size Market Share by Type in 2022
Figure 31. Beta-emitting
Figure 32. Targeted Alpha Therapy
Figure 33. World Radioimmunotherapy Market Size Market Share by Type (2018-2029)
Figure 34. World Radioimmunotherapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Radioimmunotherapy Market Size Market Share by Application in 2022
Figure 36. Solid Tumor
Figure 37. Non Hodgkin Lymphoma
Figure 38. Radioimmunotherapy Industrial Chain
Figure 39. Methodology
Figure 40. Research Process and Data Source
